Recce Pharmaceuticals Ltd

ASX:RCE Stock Report

Market Cap: AU$115.9m

Recce Pharmaceuticals Future Growth

Future criteria checks 0/6

Recce Pharmaceuticals's revenue is forecast to decline at 13.1% per annum while its annual earnings are expected to grow at 18.3% per year. EPS is expected to grow by 30.2% per annum.

Key information

18.3%

Earnings growth rate

30.2%

EPS growth rate

Pharmaceuticals earnings growth38.6%
Revenue growth rate-13.1%
Future return on equityn/a
Analyst coverage

Low

Last updated13 Dec 2024

Recent future growth updates

No updates

Recent updates

We Think Shareholders Are Less Likely To Approve A Pay Rise For Recce Pharmaceuticals Ltd's (ASX:RCE) CEO For Now

Nov 01
We Think Shareholders Are Less Likely To Approve A Pay Rise For Recce Pharmaceuticals Ltd's (ASX:RCE) CEO For Now

Here's Why We're Watching Recce Pharmaceuticals' (ASX:RCE) Cash Burn Situation

Feb 13
Here's Why We're Watching Recce Pharmaceuticals' (ASX:RCE) Cash Burn Situation

We're Hopeful That Recce Pharmaceuticals (ASX:RCE) Will Use Its Cash Wisely

Jul 28
We're Hopeful That Recce Pharmaceuticals (ASX:RCE) Will Use Its Cash Wisely

Recce Pharmaceuticals (ASX:RCE) Is In A Good Position To Deliver On Growth Plans

Dec 07
Recce Pharmaceuticals (ASX:RCE) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Recce Pharmaceuticals (ASX:RCE) Will Use Its Cash Wisely

Aug 03
We're Hopeful That Recce Pharmaceuticals (ASX:RCE) Will Use Its Cash Wisely

Recce Pharmaceuticals (ASX:RCE) Is In A Good Position To Deliver On Growth Plans

Mar 08
Recce Pharmaceuticals (ASX:RCE) Is In A Good Position To Deliver On Growth Plans

Need To Know: Recce Pharmaceuticals Ltd (ASX:RCE) Insiders Have Been Selling Shares

Feb 01
Need To Know: Recce Pharmaceuticals Ltd (ASX:RCE) Insiders Have Been Selling Shares

Could The Recce Pharmaceuticals Ltd (ASX:RCE) Ownership Structure Tell Us Something Useful?

Dec 09
Could The Recce Pharmaceuticals Ltd (ASX:RCE) Ownership Structure Tell Us Something Useful?

Earnings and Revenue Growth Forecasts

ASX:RCE - Analysts future estimates and past financials data (AUD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/20273-12-11-111
6/30/20265-10-44-112
6/30/20258-18-10-102
6/30/20245-18-13-13N/A
3/31/20246-14-11-11N/A
12/31/20237-11-9-9N/A
9/30/20236-12-11-11N/A
6/30/20234-13-13-13N/A
3/31/20234-14-14-14N/A
12/31/20223-15-15-14N/A
9/30/20223-13-12-12N/A
6/30/20223-11-9-9N/A
3/31/20222-10-8-8N/A
12/31/20211-8-7-7N/A
9/30/20211-11-8-8N/A
6/30/20212-14-8-8N/A
3/31/20211-13-8-8N/A
12/31/20201-13-8-8N/A
9/30/20201-9-6-6N/A
6/30/20201-4-4-4N/A
3/31/20201-4-3-3N/A
12/31/20191-3-3-3N/A
9/30/20191-3-3-3N/A
6/30/20191-3-3-3N/A
3/31/20191-2-2-2N/A
12/31/20182-2-2-2N/A
9/30/20181-2-2-2N/A
6/30/20181-2-2-2N/A
3/31/20181-2N/A-2N/A
12/31/20171-3N/A-2N/A
9/30/20170-3N/A-2N/A
6/30/20170-3N/A-2N/A
3/31/20170-3N/A-2N/A
12/31/20160-2N/A-2N/A
9/30/20160-4N/A-2N/A
6/30/20160-5N/A-2N/A
3/31/20160-5N/A-1N/A
12/31/20150-4N/A-1N/A
9/30/20150-2N/A0N/A
6/30/201500N/A0N/A
6/30/201400N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RCE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RCE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RCE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RCE's revenue is expected to decline over the next 3 years (-13.1% per year).

High Growth Revenue: RCE's revenue is forecast to decline over the next 3 years (-13.1% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if RCE's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 03:29
End of Day Share Price 2024/12/30 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Recce Pharmaceuticals Ltd is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pooya HemamiEdison Investment Research
Chris KallosMST Financial Services Pty Limited